Abstract
Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy.
Highlights
Differentiation is a normal process of the maturation of cells by which they become progressively more specialized
The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system
The event of mitosis is tightly coupled with the dynamic behaviour of the microtubules required for the reorganization of the microtubule system during the cell cycle; the microtubules are organized in radically different ways during the interphase and during mitosis
Summary
Differentiation is a normal process of the maturation of cells by which they become progressively more specialized. We recently identified TPPP/p25, a brain-specific intrinsically unfolded protein, which primarily targets tubulin/microtubules in normal and cancer cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have